Complexing Proteins in Botulinum Toxin Type A Drugs: a Help or a Hindrance?

Overview

Journal Biologics

Date 2011 Jan 7

PMID 21209727

Citations 56

Authors

Jurgen Frevert

Dirk Dressler

Affiliations

Soon will be listed here.

Abstract

Botulinum toxin type A is a high molecular weight protein complex containing active neurotoxin and complexing proteins, the latter of which, it is believed, protect the neurotoxin when in the gastrointestinal tract, and may facilitate its absorption. Comparisons of conventional botulinum toxin type A drugs that include complexing proteins with the complexing protein-free formulation of Xeomin(®) strongly suggest that complexing proteins do not affect diffusion of the active neurotoxin. Studies of Xeomin have also shown that complexing proteins do not enhance product stability in storage. However, complexing proteins may stimulate antibody development against botulinum toxin type A. Numerous observational studies have been published showing that some patients receiving conventional botulinum toxin may develop neutralizing antibodies, leading to antibody-induced therapy failure. Studies have shown that Xeomin is not associated with the development of neutralizing antibodies in animal models or in patients. In conclusion, complexing proteins do not contribute to the stability of botulinum toxin type A drugs and do not contribute to their therapeutic effects, but may be associated with a secondary nonresponse due to the development of neutralizing antibodies.

Citing Articles

Antinociceptive properties of intravesical/needle-free administration of abobotulinumtoxinA in a rodent model of chronic visceral pain: in vivo and histological evidence.

Auge C, Vogt M, Martin V, Lezmi S, Game X, Lluel P J Neural Transm (Vienna). 2025; .

PMID: 40089646 DOI: 10.1007/s00702-025-02906-2.

The Role of Botulinum Toxin for Masseter Muscle Hypertrophy: A Comprehensive Review.

Ferrillo M, Sommadossi E, Raciti L, Calafiore D, Mezian K, Tarantino V Toxins (Basel). 2025; 17(2).

PMID: 39998108 PMC: 11860558. DOI: 10.3390/toxins17020091.

Efficacy and Safety of RelabotulinumtoxinA, a New Ready-to-Use Liquid Formulation Botulinum Toxin: Results From the READY-1 Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial in Glabellar Lines.

Shridharani S, Moradi A, Donofrio L, Gold M, Biesman B, Chiang M Aesthet Surg J. 2024; 44(12):1330-1340.

PMID: 38913088 PMC: 11566037. DOI: 10.1093/asj/sjae131.

Comparative Study on the Duration and Efficacy of Various Botulinum Toxin Type A Injections for Reducing Masseteric Muscle Bite Force and Treating Facial Wrinkles.

Sirisuthivoranunt S, Wongdama S, Phumariyapong P, Nokdhes Y, Thongjaroensirikul P, Techapichetvanich T Dermatol Ther (Heidelb). 2024; 14(5):1315-1325.

PMID: 38724840 PMC: 11116321. DOI: 10.1007/s13555-024-01177-1.

The Role of Botulinum Toxin Type-A in Spasticity: Research Trends from a Bibliometric Analysis.

Facciorusso S, Spina S, Picelli A, Baricich A, Francisco G, Molteni F Toxins (Basel). 2024; 16(4).

PMID: 38668609 PMC: 11053519. DOI: 10.3390/toxins16040184.

References

Lietzow M, Gielow E, Le D, Zhang J, Verhagen M . Subunit stoichiometry of the Clostridium botulinum type A neurotoxin complex determined using denaturing capillary electrophoresis. Protein J. 2008; 27(7-8):420-5. DOI: 10.1007/s10930-008-9151-2. View

OHISHI I, Sugii S, Sakaguchi G . Oral toxicities of Clostridium botulinum toxins in response to molecular size. Infect Immun. 1977; 16(1):107-9. PMC: 421495. DOI: 10.1128/iai.16.1.107-109.1977. View

Dressler D, Saberi F . New formulation of Botox: complete antibody-induced treatment failure in cervical dystonia. J Neurol Neurosurg Psychiatry. 2006; 78(1):108-9. PMC: 2117793. DOI: 10.1136/jnnp.2006.093419. View

Hexsel D, DalForno T, Hexsel C, do Prado D, Lima M . A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type A. Dermatol Surg. 2007; 34(1):52-9. DOI: 10.1111/j.1524-4725.2007.34008.x. View

Pickett A, Dodd S, Rzany B . Confusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applications. J Cosmet Laser Ther. 2008; 10(3):181-3. DOI: 10.1080/14764170802094282. View

Jost W, Kohl A, Brinkmann S, Comes G . Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers. J Neural Transm (Vienna). 2004; 112(7):905-13. DOI: 10.1007/s00702-004-0234-8. View

Tang-Liu D, Aoki K, Dolly J, de Paiva A, Houchen T, Chasseaud L . Intramuscular injection of 125I-botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: time course of tissue distribution. Toxicon. 2003; 42(5):461-9. DOI: 10.1016/s0041-0101(03)00196-x. View

Dodd , Rowell , Vrabas , Arrowsmith , Weatherill . A comparison of the spread of three formulations of botulinum neurotoxin A as determined by effects on muscle function. Eur J Neurol. 1999; 5(2):181-186. DOI: 10.1046/j.1468-1331.1998.520181.x. View

Muller K, Mix E, Adib Saberi F, Dressler D, Benecke R . Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity. J Neural Transm (Vienna). 2009; 116(5):579-85. DOI: 10.1007/s00702-009-0223-z. View

10.

Benecke R, Jost W, Kanovsky P, Ruzicka E, Comes G, Grafe S . A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology. 2005; 64(11):1949-51. DOI: 10.1212/01.WNL.0000163767.99354.C3. View

11.

Dressler D . [Pharmacological aspects of therapeutic botulinum toxin preparations]. Nervenarzt. 2006; 77(8):912-21. DOI: 10.1007/s00115-006-2090-2. View

12.

Hauser D, Eklund M, Boquet P, Popoff M . Organization of the botulinum neurotoxin C1 gene and its associated non-toxic protein genes in Clostridium botulinum C 468. Mol Gen Genet. 1994; 243(6):631-40. DOI: 10.1007/BF00279572. View

13.

Bhidayasiri R, Truong D . Evidence for effectiveness of botulinum toxin for hyperhidrosis. J Neural Transm (Vienna). 2007; 115(4):641-5. DOI: 10.1007/s00702-007-0812-7. View

14.

Jin Y, Takegahara Y, Sugawara Y, Matsumura T, Fujinaga Y . Disruption of the epithelial barrier by botulinum haemagglutinin (HA) proteins - differences in cell tropism and the mechanism of action between HA proteins of types A or B, and HA proteins of type C. Microbiology (Reading). 2009; 155(Pt 1):35-45. DOI: 10.1099/mic.0.021246-0. View

15.

Dressler D . Routine use of Xeomin in patients previously treated with Botox: long term results. Eur J Neurol. 2009; 16 Suppl 2:2-5. DOI: 10.1111/j.1468-1331.2009.02877.x. View

16.

Fujinaga Y, Watanabe T, Ohyama T, Takeshi K, Moriishi K, Nakajima H . Molecular composition of Clostridium botulinum type A progenitor toxins. Infect Immun. 1996; 64(5):1589-94. PMC: 173966. DOI: 10.1128/iai.64.5.1589-1594.1996. View

17.

Brin M, Comella C, Jankovic J, Lai F, Naumann M . Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008; 23(10):1353-60. DOI: 10.1002/mds.22157. View

18.

Fujinaga Y . Transport of bacterial toxins into target cells: pathways followed by cholera toxin and botulinum progenitor toxin. J Biochem. 2006; 140(2):155-60. DOI: 10.1093/jb/mvj161. View

19.

Brin M . Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Spasticity Study Group. Muscle Nerve Suppl. 1997; 6:S208-20. DOI: 10.1002/(sici)1097-4598(1997)6+<208::aid-mus15>3.0.co;2-1. View

20.

Goschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H . Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences. Exp Neurol. 1997; 147(1):96-102. DOI: 10.1006/exnr.1997.6580. View